Over the course of our nearly seven-year partnership with Custopharm, we elevated the company into a high-value franchise featuring a robust portfolio of highly differentiated generic products, primarily injectables. Working with leadership, we invested in recruiting an experienced scientific team supported by a global network of supply and contract manufacturing partners, built a state-of-the-art research and development laboratory, and launched a commercial arm. The result: Custopharm attained a prolific output of 13 product approvals, including four first-to-market ANDA approvals and a competitive generic therapy designation, in six years. The company also grew its pipeline with eight additional products in development or pending approval. In 2022, Hikma Pharmaceuticals acquired Custopharm to expand its product portfolio and enhance its R&D capabilities.